TMO

Thermo Fisher Scientific raised its full-year 2026 organic revenue growth guidance to 4% following strong Q3 results with $12.14 billion in revenue and 6% organic growth. The company is leveraging AI integration to reduce manual laboratory setup time by 90%, accelerating workflows and boosting recurring sales. Strategic acquisitions like Clario are expanding clinical development capabilities and creating revenue synergies, positioning the company for durable margin expansion amid strengthening biopharmaceutical research activity.

Thermo Fisher Scientific (TMO) reported quarterly earnings of $6.68 per share, beating consensus estimates of $6.4 and surpassing revenue expectations at $12.14 billion. The company has outperformed the market by 17.3% year-to-date and maintains a Zacks Rank #2 (Buy) rating with favorable estimate revision trends. Integer Holdings (ITGR), another medical device company, is expected to report declining earnings and revenues in its upcoming quarter.

Thermo Fisher Scientific (TMO) is highlighted as a stock well-positioned to maintain its earnings-beat streak, with a positive Earnings ESP of +0.07% and a Zacks Rank #2 (Buy) rating. The company has demonstrated consistent earnings surprises, averaging 5.11% over the past two quarters, with its next earnings report expected on October 21, 2026.